Immunologic Research

, Volume 23, Issue 2–3, pp 263–272 | Cite as

VEGF as a mediator of tumor-associated immunodeficiency

  • Joyce E. Ohm
  • David P. CarboneEmail author


Decreased immune function in cancer patients is well-characterized (I), and tumor cells have developed a variety of mechanisms, to avoid anti-tumor immune responses (2–8). One mechanism for inhibition of immune cell function by tumors in the production of soluble factors, such as IL-10, TNF, TGF-β, and Vascular Endothelial Growth Factor (VEGF). The effects of these factors appear, to be twofold: To inhibit effect or function and to impair the development of immune cells by acting on earlier stages of immunopoiesis. Immune suppression by tumors is accomplished by a variety of cellular and molecular mechanisms, and virtually all branches of the immune system can be affected. VEGF and its receptors have profound effects on the early development and differentiation of both vascular endothelial and hematopoetic progenitors (9). It induces proliferation of mature endothelial cells and is an important component in the formation of tumor neovasculature (10). VEGF is abundantly expressed by a large percentage of solid tumors and this over-expression is closely associated with a poor prognosis (11, 12). Some of the earliest hematopoetic progenitors express receptors for VEGF (13), and we have demonstrated that VEGF causes a defect in the functional maturation of dendritic cells (DC) from progenitors. This developmental defect is associated with impaired activation of NF-κB (14–17). This review describes research demonstrating that VEGF is not only important for tumor vascularization, but is also a key factor produced by solid tumors to inhibit recognition and destruction of tumor cells by the immune system.

Key Words

VEGF Cellular Differentiation Growth Factors Transcription Factors Tumor Immunity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kayanaugh DY, Carbone DP: Immunologic dysfunction in cancer. Hematol-Oncol Clin, North America 1996;10:927–951.CrossRefGoogle Scholar
  2. 2.
    Johnsen AK, Templeton DJ, Sy M, Harding CV: Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1999;163:4224–4231.PubMedGoogle Scholar
  3. 3.
    Finke J, Ferrone S, Frey A, Mufson A, Ochoa A: Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today 1999;20:158–160.PubMedCrossRefGoogle Scholar
  4. 4.
    Antonia SJ, Extermann M, Flavell RA: Immunologic nonresponsiveness to tumors. Crit Rev Oncog 1998;9:35–41.PubMedGoogle Scholar
  5. 5.
    Kiessling R, Wasserman K, Horiguchi S et al.: Tumor-induced immune dysfunction. Cancer Immunol Immunother 1999;48:353–362.PubMedCrossRefGoogle Scholar
  6. 6.
    Shu S, Plautz GE, Krauss JC, Chang AE: Tumor immunology. JAMA 1997;278:1972–1981.PubMedCrossRefGoogle Scholar
  7. 7.
    Pawelec G, Zeuthen J, Kiessling R: Escape from host-antitumor immunity. Crit Rev Oncog 1997; 8:111–141.PubMedGoogle Scholar
  8. 8.
    Markiewicz MA, Gajewski TF: The immune system as anti-tumor sentinel: molecular requirements for an anti-tumor immune response. Crit Rev Oncog 1999;10:247–260.PubMedGoogle Scholar
  9. 9.
    Ferrara N, Carver-Moore K, Chen H, et al.: Heterozy gous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439–442.PubMedCrossRefGoogle Scholar
  10. 10.
    Ferrara N, Davis-Smyth, T: The Biology of Vascular Endothelial Growth Factor. Endocrine Rev 1997;18:4–25.CrossRefGoogle Scholar
  11. 11.
    Toi M, Hoshina S, Takayanagi T, Tominaga T: Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994;85:1045–1049.PubMedGoogle Scholar
  12. 12.
    Toi M, Taniguchi T, Yamamoto Y, Kurisaki T, Suzuki H, Tominaga T: Clinical significance of the determination of angiogenic factors. Eur J Cancer 1996;32A:2513–2519.PubMedCrossRefGoogle Scholar
  13. 13.
    Ziegler BL, Valtieri M, Porada GA, et al.: KDR receptor: a key marker defining hematopoietic stem cells. Science 1999;285:1553–1558.PubMedCrossRefGoogle Scholar
  14. 14.
    Gabrilovich DI, Chen HL, Girgis KR, et al.: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nature Med 1996;2:1096–1103.PubMedCrossRefGoogle Scholar
  15. 15.
    Gabrilovich D, Ishida T, Oyama T, et al.: Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150–4166.PubMedGoogle Scholar
  16. 16.
    Ishida T, Oyama T, Carbone DP, Gabrilovich DI: Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J Immunol 1998;161:4842–4851.PubMedGoogle Scholar
  17. 17.
    Oyama T, Ran S, Ishida T, et al.: Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J Immunol 1998;160:1224–1232.PubMedGoogle Scholar
  18. 18.
    Boon T: Towarda genetic analysis of tumor rejection antigens. Adv Cancer Res 1992;58:177–210.PubMedCrossRefGoogle Scholar
  19. 19.
    Boon T, van der Bruggen P: Human tumor antigens recognized by T lymphocytes. J Exp Med 1996; 183:725–729.PubMedCrossRefGoogle Scholar
  20. 20.
    Boon T, Cerottini J-C, Van der Eynde B, Van Der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337–365.PubMedCrossRefGoogle Scholar
  21. 21.
    Ciernik IF, Carbone DP: Tumor Suppressor Gene-Derived Peptide Antigens. Meth Enzymol 1995; 8:225–233.CrossRefGoogle Scholar
  22. 22.
    Coulie PG, Lehmann F, Lethe B, et al.: A mutated intron sequence codes foran antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 1995;92:7976–7980.PubMedCrossRefGoogle Scholar
  23. 23.
    Van Pel A, De Plaen E, Lurquin C, et al.: Identification of genes encoding T cell defined tumantigens. Int Symp Princess Takamatsu Cancer Res Fund 1988;19:255–263.PubMedGoogle Scholar
  24. 24.
    Alcalay J, Kripke ML: Antigen-presenting activity of draining lymph node cells from mice painted with a contact allergen during ultraviolet carcinogenesis. J Immunol 1991;146:1717–1721.PubMedGoogle Scholar
  25. 25.
    Erroi A, Sironi M, Chiaffarino F, Chen ZG, Mengozzi M, Mantovani A: IL1 and IL6 released by tumor-associated macrophages from human ovarian carcinoma. Int J Cancer 1989;41:65–68.CrossRefGoogle Scholar
  26. 26.
    Watson GA, Lopez DM: Aberrant antigen presentation by macrophages from tumor-bearing mice is involved in the down-regulation of their T cell responses. J Immunol 1995;155:3124–3134.PubMedGoogle Scholar
  27. 27.
    Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP: Dendritic cells in anti-tumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996; 170:111–119.PubMedCrossRefGoogle Scholar
  28. 28.
    Ferrara N Houck K, Jakeman L, Leung DW: Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocrine Rev 1992;13:18–32.CrossRefGoogle Scholar
  29. 29.
    Kondo S, Asano M, Matsuo K, Ohmori I, Suzuki H: Vascular endothelial growth factor/vascular pemeability factor is detectable in thesera of tumor-bearing mice and cancer patients. Bioch Biophys Acta 1994;1221:211–214.CrossRefGoogle Scholar
  30. 30.
    Ellis LM, Fidler IJ: Angiogenesis and metastasis. Eur J Cancer 1996;32A:2451–2460.PubMedCrossRefGoogle Scholar
  31. 31.
    Hoehn GT, Stokland T, Amin S, et al.: Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38-stem/progenitor cells. Oncogene 1996;12:440–448.Google Scholar
  32. 32.
    Katoh O, Tauchi H, Kawaishi K, Kimura A, Satow Y: Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoetic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 1995;55:5687–5692.PubMedGoogle Scholar
  33. 33.
    Broxmeyer HE, Cooper S, Li ZH, et al.: Myeloid progenitor cells regulatory effects of vascular endothelial cell growth factor. Inter J Hematol 1995;62:203–215.CrossRefGoogle Scholar
  34. 34.
    Almand B, Resser JR, Lindman B, et al.: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755–1766.PubMedGoogle Scholar
  35. 35.
    Gabrilovich DI, Ishida T, Nadaf S, Ohm JE, Carbone DP: Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 1999;5:2963–2970.PubMedGoogle Scholar
  36. 36.
    Grossmann M, Nakamura Y, Grumont R, Gerondakis S: New insights into the roles of ReL/NF-kappa B transcription factors in immune function, hemopoiesis and human disease. Int J Biochem Cell Biol 1999;31:1209–1219.PubMedCrossRefGoogle Scholar
  37. 37.
    Ghosh S, May MJ, Kopp EB: NF-kappa B and Re1 proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998;16:225–260.PubMedCrossRefGoogle Scholar
  38. 38.
    Wulczyn FG, Krappmann D, Scheidereit C: The NF-kappa B/Re1 and 1 kappa B gene families: mediators of immune response and inflammation. J Mol Med 1996;74:749–769.PubMedCrossRefGoogle Scholar
  39. 39.
    Baeuerle PA, Henkel T: Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 1994;12:141–179.PubMedGoogle Scholar
  40. 40.
    Stankovski I, Baltimore, D: NF-κB Activation: The IκB Kinase Revealed. Cell 1997;91:299–302.CrossRefGoogle Scholar
  41. 41.
    Thanos D, Maniatis T: NF-κB: A Lesson in Family Values. Cell 1995;80:529–532.PubMedCrossRefGoogle Scholar
  42. 42.
    Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D, Miyamoto S: Re1/NF-kappa B/I kappa B family: intimate tales of association and dissociation. Genes Dev 1995;9:2723–2735.PubMedCrossRefGoogle Scholar
  43. 43.
    Baeuerle PA, Baltimore D: NF-kappa B: ten years after. Cell 1996;87:13–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Baldwin AS: The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649–683.PubMedCrossRefGoogle Scholar
  45. 45.
    Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9–22.PubMedGoogle Scholar
  46. 46.
    Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M: Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998;95:9349–9354.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 2001

Authors and Affiliations

  1. 1.Department of Medicine and Vanderbilt-Ingram Cancer CenterVanderbilt University Medical CenterNashville

Personalised recommendations